Sarepta Therapeutics Inc SRPT:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 11/25/22 EST
114.30quote price arrow down-0.27 (-0.24%)
Close
114.57UNCH (UNCH)
Volume
213,478
52 week range
61.28 - 120.23
Loading...
  • Open114.57
  • Day High115.48
  • Day Low113.79
  • Prev Close114.57
  • 52 Week High120.23
  • 52 Week High Date09/09/22
  • 52 Week Low61.28
  • 52 Week Low Date06/16/22

Key Stats

  • Market Cap10.057B
  • Shares Out87.78M
  • 10 Day Average Volume0.77M
  • Dividend-
  • Dividend Yield-
  • Beta1.06
  • YTD % Change27.23

KEY STATS

  • Open114.57
  • Day High115.48
  • Day Low113.79
  • Prev Close114.57
  • 52 Week High120.23
  • 52 Week High Date09/09/22
  • 52 Week Low61.28
  • 52 Week Low Date06/16/22
  • Market Cap10.057B
  • Shares Out87.78M
  • 10 Day Average Volume0.77M
  • Dividend-
  • Dividend Yield-
  • Beta1.06
  • YTD % Change27.23

RATIOS/PROFITABILITY

  • EPS (TTM)-8.21
  • P/E (TTM)-13.96
  • Fwd P/E (NTM)-19.82
  • EBITDA (TTM)-493.725M
  • ROE (TTM)-159.10%
  • Revenue (TTM)876.047M
  • Gross Margin (TTM)83.91%
  • Net Margin (TTM)-81.76%
  • Debt To Equity (MRQ)358.08%

EVENTS

  • Earnings Date02/27/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sarepta Therapeutics Inc

 

Profile

MORE
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (Duchenne), Limb-girdle muscular dystrophies (LGMDs) and other...
M. Kathleen Behrens Ph.D.
Independent Chairwoman of the Board
Douglas Ingram Esq., J.D.
President, Chief Executive Officer, Director
Ian Estepan
Chief Financial Officer, Executive Vice President
Louise Rodino-Klapac Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R and D
William Ciambrone
Executive Vice President - Technical Operations
Address
215 1st St Ste 415
Cambridge, MA
02142-1213
United States

Top Peers

SYMBOLLASTCHG%CHG
NVCR
Novocure Ltd
75.00UNCHUNCH
NBIX
Neurocrine Biosciences Inc
122.15UNCHUNCH
HALO
Halozyme Therapeutics Inc
54.67UNCHUNCH
MEDP
Medpace Holdings Inc
217.81UNCHUNCH
NVZMY
Novozymes A/S
57.13+0.89+1.58%